Empliciti (Elotuzumab) for Myeloma

Overview
Empliciti is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma in people who have tried other therapies. Empliciti is often combined with Pomalyst or Revlimid and a corticosteroid. Empliciti is also known by its drug name, elotuzumab.

Empliciti is an anti-cancer drug. Empliciti is a member of a class of drugs called biologics. Empliciti is a monoclonal antibody, a man-made drug that acts like an antibody, designed to attach to myeloma cells. Empliciti is believed to work by helping the immune system recognize and attack myeloma cells.

How do I take it?
Empliciti is administered as an intravenous infusion.

Side effects
The FDA-approved label for Empliciti lists common side effects including fatigue, diarrhea, fever, constipation, cough, cold or flu symptoms, nausea, loss of appetite, peripheral neuropathy (pain, tingling, or numbness in the extremities), and pneumonia.

Rare but serious side effects listed for Empliciti include infusion reactions, increased risk for infection, increased risk for developing other cancers, and liver damage.

For more details about this treatment, visit:

Empliciti — Bristol-Myers Squibb
https://www.empliciti.com

Drug Therapy for Multiple Myeloma — American Cancer Society
https://www.cancer.org/cancer/multiple-myeloma/...